Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, etoricoxib attenuated NGF expression, but enhanced TGF-β expression in OA-affected chondrocytes.
|
31495059 |
2020 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The potential role of NGF in osteoarthritis and chronic low-back pain signaling is also examined to provide a mechanistic basis for the observed efficacy of NGF-Abs in clinical trials of these particular pain states.
|
31145219 |
2019 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These emerging OA drugs such as bone morphogenetic protein-7 (BMP-7), fibroblast growth factor-18 (FGF-18), human serum albumin (HSA), interleukin-1 (IL-1) inhibitor, β-Nerve growth factor (β-NGF) antibody, matrix extracellular phosphoglycoprotein (MEPE) and inverse agonist of retinoic acid-related orphan receptor alpha (RORα) etc. have shown potential to modify progression of OA with minimal adverse effects.
|
31312184 |
2019 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A variety of pharmacological options have been investigated in treating OA, including existing therapies previously used for treating other arthritides (such as colchicine and hydroxychloroquine) and new therapies targeting pain (including monoclonal antibodies to nerve growth factor and intra-articular trans-capsaicin).
|
31621576 |
2019 |
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We confirmed expressions of NGF and TrkA were significantly up-regulated in OA.
|
30562625 |
2019 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In multivariate analysis, COMP (OR 1.24, 95% CI 1.06 to 1.46), resistin (OR 1.26, 95% CI 1.07 to 1.48), MCP-1 (OR 1.10, 95% CI 0.07 to 1.48) and NGF (OR<0.001, 95% CI <0.001 to 0.25) were found to be independently associated with PsA versus OA.
|
30910989 |
2019 |
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased NGF expression in osteochondral channels and increased osteoclast density appear to be key features associated with bone pain in knee OA.
|
30663865 |
2019 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study demonstrates therapeutic efficacy of a novel NGF vaccine strategy that reversibly alleviates spontaneous pain behaviour in surgically induced murine OA.
|
30862648 |
2019 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CRISPR-mediated ablation of NGF alleviates OA pain, and deletion of MMP13-1β or IL-1β attenuates structural damage in a post-traumatic OA model.
|
30842121 |
2019 |
Degenerative polyarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Aiming to delineate novel neuro-immune mechanisms for NGF/TrkA signalling in osteoarthritis (OA) pain, we evaluated inflammatory changes in the knee joints following injection of monoiodoacetate (MIA) in mice carrying a TrkA receptor mutation (P782S; TrkA KI mice).
|
28844566 |
2018 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we will discuss TGF-β, NGF, Hedgehog and Wnt, the four growth factors which have received extensive attention in the field of OA and clinical/translational interrogation about their application in OA therapies.
|
30624091 |
2018 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nerve growth factor (NGF) sequestration has been trialed for the management of inflammatory bone pain (osteoarthritis), and there is significant evidence for interaction of NGF with bone marrow nociceptors.
|
28955292 |
2017 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Areas covered: This manuscript is a review that examines both the pharmacological properties and clinical studies of tanezumab, the most widely studied antibody to NGF, for management of osteoarthritis (OA) and low back pain.
|
27936977 |
2017 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among mediators involved in OA pain, nerve growth factor (NGF) is in the focus because antibodies against NGF significantly reduce OA pain.
|
29163027 |
2017 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?
|
27672741 |
2017 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study suggests a stage-related modulation of β-NGF and its receptors in the inflammatory process of OA.
|
28253191 |
2017 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Growing evidence links the expression of CD271, a nerve growth factor (NGF) receptor by native bone marrow-resident MSCs to a wider role for neurotrophins in OA pathobiology, the implications of which require exploration since anti-NGF therapy might worsen OA.
|
29118440 |
2017 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This narrative review describes the current status of NGF-blockade for the treatment of OA pain.
|
28967370 |
2017 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nerve growth factor (NGF) antagonism is on the verge of becoming a powerful analgesic treatment for numerous conditions, including osteoarthritis and lower back pain.
|
28441116 |
2017 |
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we examined the role of macrophages in the production and regulation of synovial (SYN) NGF in osteoarthritic knee joints by examining the mRNA expression of TNF-α and IL-1β in freshly isolated CD14-positive (macrophage-rich fraction) and CD14-negative cells (fibroblast-rich fraction) in synovial tissue from OA patients by quantitative polymerase chain reaction.
|
28677145 |
2017 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since NGF blocking is an efficient way to inhibit OA-associated pain, we summarize four categories of drugs that target NGF/tropomyosin receptor kinase A (TrkA) signaling.
|
28814877 |
2017 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the role of macrophages as a regulator and producer of nerve growth factor (NGF) in the synovial tissue (ST) of osteoarthritis (OA) joints, the gene expression profiles of several inflammatory cytokines in the ST, including synovial macrophages and fibroblasts, of OA mice (STR/Ort) were characterized.
|
27635406 |
2016 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed NGF expression on mRNA level with QPCR and stained human OA cartilage for NGF immunohistochemically.
|
25529198 |
2015 |
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
MCF2L regulates a nerve growth factor (NGF), and treatment with a humanized monoclonal antibody against NGF is associated with reduction in pain and improvement in function for knee OA patients.
|
21871595 |
2011 |
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SF cell analysis revealed a clear BDNF and NGF mRNA expression, with significantly higher NGF expression in RA and SpA patients than in the OA group.
|
19490633 |
2009 |